Similarly, increasingly expressed GPCRs in cancer cells (for example, GPRC5A in PDAC and colon cancer cells and GPR68 in PDAC CAFs), according to Paul et al., might add to the malignant phenotype, act as biomarkers, and/or constitute new drug targets for cancer therapy [388,389]. This evidence concerns the gene GPRC5A and cancer.